CD4 and neoplasm: In fact, ROCKi, combined with an anti-PD-1 antibody, decreased the growth of the anti-PD-1-resistant melanomas through both the intrinsic tumour’s cell death and the relief of immunosuppression, without affecting tumour infiltration by CD4+ or CD8+ T cells [68].